121 related articles for article (PubMed ID: 3043232)
1. US looking for short cuts to speed drug approval.
Ezzell C
Nature; 1988 Aug; 334(6183):553. PubMed ID: 3043232
[No Abstract] [Full Text] [Related]
2. Investigational new drug, antibiotic, and biological product applications; clinical hold and termination--FDA. Final rule.
Fed Regist; 1992 Apr; 57(73):13244-9. PubMed ID: 10118458
[TBL] [Abstract][Full Text] [Related]
3. AIDS and the politics of drug lag.
Vogel D
Public Interest; 1989; (96):73-85. PubMed ID: 10294053
[No Abstract] [Full Text] [Related]
4. Desperation drugs. Frustrated AIDs patients are spurring the FDA to relax the rules of the game.
Begley S; Hager M; Wilson L
Newsweek; 1989 Aug; 114(6):48-9, 51. PubMed ID: 10293942
[No Abstract] [Full Text] [Related]
5. Investigational new drug regs: icing or cake?
Margolis RE
Healthspan; 1988 Dec; 5(11):25-6. PubMed ID: 10291398
[No Abstract] [Full Text] [Related]
6. Antiviral AIDS drug nears approval.
Science; 1991 Apr; 252(5003):206-7. PubMed ID: 1901425
[No Abstract] [Full Text] [Related]
7. Clinical trial that led to FDA approval of zidovudine is published.
Clin Pharm; 1987 Oct; 6(10):752. PubMed ID: 3333341
[No Abstract] [Full Text] [Related]
8. A faster track for AIDS drugs?
Kosterlitz J
Natl J (Wash); 1989 Jul; 21(30):1931. PubMed ID: 10293944
[No Abstract] [Full Text] [Related]
9. DdI approval offers second chance.
Albert SG
Am Pharm; 1991 Dec; NS31(12):6. PubMed ID: 1763779
[No Abstract] [Full Text] [Related]
10. Great expectations: is the U.S. doing its best to beat AIDS?. Interview by Don McLearn.
Parkman PD
FDA Consum; 1989 Feb; 23(1):36-8. PubMed ID: 10312853
[No Abstract] [Full Text] [Related]
11. FDA 'remains committed' to quick approval of AIDS drugs.
Am Pharm; 1994 Dec; NS34(12):14. PubMed ID: 7856502
[No Abstract] [Full Text] [Related]
12. Cancer and AIDS groups push for changes in drug approval process.
Anderson LF
J Natl Cancer Inst; 1989 Jun; 81(11):829-31. PubMed ID: 2724348
[No Abstract] [Full Text] [Related]
13. Europe learns from US drug mistakes.
Alcorn K
J Int Assoc Physicians AIDS Care; 1996 Mar; 2(3):39. PubMed ID: 11363346
[TBL] [Abstract][Full Text] [Related]
14. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
15. IRB/FDA requirements relevant to HIV/AIDS clinical trials in correctional settings.
Cohen J;
AIDS Read; 2001 Jan; 11(1):41-2. PubMed ID: 11215087
[TBL] [Abstract][Full Text] [Related]
16. FDA evaluates accelerated approval process. Food and Drug Administration.
Common Factor; 1995 Apr; (no 10):18. PubMed ID: 11362343
[TBL] [Abstract][Full Text] [Related]
17. Editorial: time to end the death trials.
James JS
AIDS Treat News; 1996 Aug; (no 252):1-4. PubMed ID: 11363751
[TBL] [Abstract][Full Text] [Related]
18. Investigational new drug regulations.
AORN J; 1988 Jun; 47(6):1473. PubMed ID: 3389785
[No Abstract] [Full Text] [Related]
19. FDA Advisory Committee stalemates on delavirdine.
AIDS Patient Care STDS; 1997 Apr; 11(2):96-7. PubMed ID: 11361773
[No Abstract] [Full Text] [Related]
20. FDA reform in Congress: AIDS community absent. Food and Drug Administration.
James JS
AIDS Treat News; 1995 Apr; (no 220):4-5. PubMed ID: 11362320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
